LABU ETF News

We have highlighted a few leveraged equity ETFs that have piled up more than 25% returns so far in the fourth quarter and could continue to be investors' darlings.

These leveraged ETFs posted solid gains last week.

Here is a look at ETFs that currently offer attractive short selling opportunities. The ETFs included in this list are rated as sell candidates for two reasons. First, each of these funds is deemed to

Here is a look at ETFs that currently offer attractive short selling opportunities. The ETFs included in this list are rated as sell candidates for two reasons. First, each of these funds is deemed to

Read a comparison of BIB and LABU and a description of the characteristics and historical performance of these leveraged biotech ETFs.

With one of the industry's marquee conferences recently ending, traders may want to consider the Direxion Daily Healthcare Bull 3X Shares (NYSE: CURE) and the Direxion Daily S&P; Biotech Bull 3X Shar

For the past month, leveraged exchange-traded fund (ETF) traders have been feasting off opportunities in gold, biotech, large caps, and semiconductors as the U.S.-China trade deal went awry. The fligh

Exchange-traded funds (ETFs) are often aimed at conservative investors with long-term time horizons. Many of the largest ETFs on the market today are designed to provide cost-effective exposure to bas

No summary available.

Leveraged biotechnology exchange traded funds (ETFs) are known to make big moves, but sometimes those moves are not always about price action. What Happened Entering Monday, the Direxion Daily S&P; Bi

No summary available.

No summary available.